Weddle v. Wakemed Health & Hosps.

2025 NCBC 71
North Carolina Business Court·Decided November 17, 2025·No. 22-CVS-13860·Published

Opinion

Weddle v. WakeMed Health & Hosps., 2025 NCBC 71.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION

WAKE COUNTY 22CVS013860-910

TRACE WEDDLE, LINDA MATTHIAE, and KIM NAUGLE, on behalf of themselves and all others similarly situated,

Plaintiffs, ORDER AND OPINION ON MOTION FOR FINAL APPROVAL OF CLASSv . ACTION SETTLEMENT AND PETITION FOR ATTORNEYS’ FEES WAKEMED HEALTH AND HOSPITALS d/b/a WAKEMED,

Defendant.

1. Plaintiffs Trace Weddle, Linda Matthiae, and Kim Naugle have moved for final approval of a settlement of this class action and have filed a related petition for attorneys’ fees and expenses. (ECF Nos. 110, 112.) Both are unopposed. For the reasons given below, the Court enters Final Judgment, APPROVES the proposed settlement, DISMISSES all class claims, and GRANTS in part the fee petition.

James Scott Farrin, by Thomas M. Wilmoth and Gary W. Jackson; and CohenMalad, LLP, by Amina A. Thomas and Lynn A. Toops, for Plaintiff Trace Weddle.

Markovits, Stock & DeMarco, LLC, by Terence R. Coates and Jonathan T. Deters; Bryson Harris Suciu & DeMay, PLLC, by Scott C. Harris and James DeMay; and Milberg Coleman Bryson Phillips Grossman, PLLC, by Gary M. Klinger, for Plaintiff Linda Matthiae.

Lockridge Grindal Nauen PLLP, by Kate M. Baxter-Kauf and Maureen Kane Berg; CR Legal Team, LLP, by James Harrell and Peter H. Burke;

and Bryson Harris Suciu & DeMay, PLLC, by Scott C. Harris and James DeMay, for Plaintiff Kim Naugle.

Alston & Bird LLP, by Matthew P. McGuire, Kristine McAlister Brown, Donald Houser, and Brandon Springer, for Defendant WakeMed Health & Hospitals.

Conrad, Judge.

I.

BACKGROUND

2. Plaintiffs are patients or former patients of Defendant WakeMed Health and Hospitals. In November 2022, Plaintiffs sued WakeMed and asserted claims relating to its use of third-party tracking software on its website and patient portal. The software is called the Meta Pixel. “Meta” refers to Meta Platforms, Inc.—better known as the company that owns Facebook. “Pixel” refers to software code created by Meta that can be put into a website to collect data. According to Plaintiffs, WakeMed’s use of the Pixel gave Meta unauthorized access to patients’ personal and medical data for advertising and marketing purposes. Based on these allegations, Plaintiffs asserted a variety of claims, both individually and on behalf of a putative class of similarly situated individuals. Early motion practice narrowed these claims; the remaining claims are for negligence, breach of implied contract, and breach of fiduciary duty. See generally Weddle v. WakeMed Health, 2023 NCBC LEXIS 162 (N.C. Super. Ct. Dec. 4, 2023) (dismissing certain claims).

3. In early 2025, the parties reached a settlement of all individual and class claims. The key terms of the settlement are straightforward. WakeMed agreed to pay $2,450,000 into a non-reversionary settlement fund. A third of that amount is allocated to the fees and expenses of class counsel (subject to judicial approval), and a smaller portion is allocated to administration costs. After those deductions, the remaining funds are available to pay class members a pro rata amount. Although class members must submit a claim to receive payment, no evidence of loss is required to substantiate a claim. In return, class members who do not opt out of the settlement release their claims.

4. Plaintiffs moved for preliminary approval of the settlement agreement and conditional class certification in April 2025. (ECF No. 101.) The Court entered an order that (1) preliminarily approved the settlement agreement; (2) conditionally certified the settlement class; (3) approved the claims process and directed that notice be given to putative class members; (4) set a schedule for submission of a motion for final settlement approval and of any objections; and (5) scheduled a hearing to determine the fairness, reasonableness, and adequacy of the settlement terms. (See ECF No. 105.)

5. In keeping with the Court’s preliminary approval, the settlement administrator sent notice by mail and, when possible, by e-mail to almost 500,000 putative class members. As in any situation like this, some mailings were returned undeliverable, and some e-mails were rejected. The administrator used forwarding addresses and other investigative means to make as many second attempts as possible. Through these efforts, the administrator estimates having reached 97% of the class. (See generally ECF No. 115.)

6. In July 2025, Plaintiffs filed a motion for an award of attorneys’ fees, reimbursement of litigation expenses, and class representative service awards. (ECF No. 110.) Two months later, Plaintiffs timely filed their motion for final approval of the settlement. (ECF No. 112.)

7. The Court held a fairness hearing on 16 October 2025, at which counsel for Plaintiffs and WakeMed appeared. No member of the proposed class attended the hearing. The parties’ submissions show that sixteen class members opted out of the settlement and just one objected. (See ECF No. 113.3.) Following the hearing, the Court entered an order calling for additional information related to the requested attorneys’ fees and litigation expenses. Now that Plaintiffs have timely filed this additional information, the motions are ripe. (See ECF Nos. 116, 117, 117.1–117.6.)

II.

CLASS CERTIFICATION AND SETTLEMENT APPROVAL

8. “The class action is an exception to the usual rule that litigation is conducted by and on behalf of the individual named parties only.” Comcast Corp. v. Behrend, 569 U.S. 27, 33 (2013) (citation and quotation marks omitted). Because a class-action settlement binds individuals who have not appeared in the litigation, it “raises unique due process concerns” and requires “court approval.” Ehrenhaus v. Baker, 216 N.C. App. 59, 72 (2011) (“Ehrenhaus I”). In their motion, and with WakeMed’s consent, Plaintiffs contend that the proposed settlement is fair, reasonable, and adequate. They ask the Court to approve it and certify a settlement class.

9. Class Certification. Rule 23 of the North Carolina Rules of Civil Procedure governs class certification. Under that rule, a court may certify a class action if the following requirements are met:

(1) the existence of a class, (2) the named representative will fairly and adequately represent the interests of all class members, (3) there is no conflict of interest between the representative and class members, (4) class members outside the jurisdiction will be adequately represented, (5) the named party has a genuine personal interest in the outcome of the litigation, (6) class members are so numerous that it is impractical to bring them all before the court, and (7) adequate notice of the class action is given to class members.

Chambers v. Moses H. Cone Mem. Hosp., 2022 NCBC LEXIS 122, at *5 (N.C. Super. Ct. Oct. 19, 2022); accord Moss v. Towell, 2018 NCBC LEXIS 20, at *6–7 (N.C. Super. Ct. Mar. 6, 2018); In re PokerTek Merger Litig., 2015 NCBC LEXIS 10, at *9 (N.C. Super. Ct. Jan. 22, 2015); see also N.C. R. Civ. P. 23. In short, a certifiable class exists “when the named and unnamed members each have an interest in either the same issue of law or of fact, and that issue predominates over issues affecting only individual class members.” Crow v. Citicorp Acceptance Co., 319 N.C. 274, 280 (1987).

10. Having considered all matters of record, the Court concludes that the requirements of Rule 23 have been met and that certification of the settlement class is appropriate.

Free access — add to your briefcase to read the full text and ask questions with AI

Weddle v. Wakemed Health & Hosps., 2025 NCBC 71 (N.C. Super. Ct. 2025).

2025 NCBC 71 (Weddle v. Wakemed Health & Hosps.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Comcast Corp. v. Behrend
133 S. Ct. 1426 (Supreme Court, 2013)
Crow v. Citicorp Acceptance Co., Inc.
354 S.E.2d 459 (Supreme Court of North Carolina, 1987)
Hamilton v. Memorex Telex Corp.
454 S.E.2d 278 (Court of Appeals of North Carolina, 1995)
Ehrenhaus v. Baker
717 S.E.2d 9 (Court of Appeals of North Carolina, 2011)
Ehrenhaus v. Baker
776 S.E.2d 699 (Court of Appeals of North Carolina, 2015)
Jennifer Clemens v. Execupharm Inc
48 F.4th 146 (Third Circuit, 2022)
Ge Betz, Inc. v. Conrad
752 S.E.2d 634 (Court of Appeals of North Carolina, 2013)